These findings suggest intrinsic differences between the B16 and BPR20 melanomas regarding potential mechanisms underlying the effectiveness of STING agonist-based interventions, which may reflect variance in the operational regulatory action of ISG15 across these two unrelated tumor models. Here, STING1 is linked to melanoma.